Phase I Trial of a Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Advanced Malignancies

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Clinical Cancer Research

• Publication date

  2009-11-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-09-1241PMID 19903778PMCID PMC2784003
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase II trial of sorafenib in metastatic thyroid cancer.

  2009cited by this paper
• Sorafenib for the treatment of unresectable hepatocellular carcinoma.

  2009cited by this paper
• A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy

  2008cited by this paper
• Drug Target Identification Using Side-Effect Similarity

  2008cited by this paper
• RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer

  2008cited by this paper
• Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib

  2008cited by this paper
• Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib

  2008cited by this paper
• Sorafenib for the treatment of unresectable hepatocellular carcinoma

  2008cited by this paper
• Phase I Study of Alternate-Week Administration of Tipifarnib in Patients with Myelodysplastic Syndrome

  2008cited by this paper
• Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib.

  2008cited by this paper
• Phase II trial of sorafenib in advanced thyroid cancer.

  2008cited by this paper
• A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia

  2007cited by this paper
• Sorafenib in advanced clear-cell renal-cell carcinoma.

  2007cited by this paper
• Biomarkers in Gastrointestinal Stromal Tumor: Should We Equate Blood-Based Pharmacodynamics with Tumor Biology and Clinical Outcomes?

  2007cited by this paper
• Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine‐kinase inhibitor

  2006cited by this paper
• Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.

  2006cited by this paper
• Development of farnesyl transferase inhibitors: a review.

  2005cited by this paper
• Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

  2005cited by this paper
• Farnesyltransferase inhibitor therapy in acute myelogenous leukemia.

  2005cited by this paper
• Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy.

  2005cited by this paper
• Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma.

  2004cited by this paper
• Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.

  2004cited by this paper
• Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome.

  2004cited by this paper
• Tumorigenesis: Flying beneath the radar

  2004cited by this paper
• Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer.

  2004cited by this paper
• Farnesyl transferase inhibitors in myeloid malignancies.

  2003cited by this paper
• Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting.

  2003cited by this paper
• Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer.

  2002cited by this paper
• Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.

  2001cited by this paper
• Discovery of a novel Raf kinase inhibitor.

  2001cited by this paper
• Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer.

  2000cited by this paper
• Measuring response in solid tumors: unidimensional versus bidimensional measurement.

  1999cited by this paper

• Melanoma: Pathogenesis and Targeted Therapy

  2026cites this paper
• Neoadjuvant Therapy with Multikinase Inhibitors for Locally Advanced Differentiated Thyroid Cancer: A Systematic Review

  2025cites this paper
• The Revolution of Targeted Therapies in Thyroid Cancer Treatment: Present and Future Promising Anti-Cancer Drugs

  2025cites this paper
• Next-Generation Sequencing in Sporadic Medullary Thyroid Cancer Patients: Mutation Profile and Disease Aggressiveness

  2024cites this paper
• The Evolving Treatment Landscape of Medullary Thyroid Cancer

  2023cites this paper
• Targeted radionuclide therapy in endocrine-related cancers: advances in the last decade

  2023cites this paper
• Targeting HRAS in Head and Neck Cancer

  2022cites this paper
• Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives

  2021cites this paper
• Association analysis between the interaction of RAS family genes mutations and papillary thyroid carcinoma in the Han Chinese population

  2021cites this paper
• Utilizing the circulating tumor markers in diagnosis and management of medullary thyroid cancer.

  2021cites this paper
• Multiple endocrine neoplasia type 2 (MEN2).

  2021cites this paper
• Calcitonin as a biomarker of C cell disease: recent achievements and current challenges

  2020cites this paper
• Kinome directed target discovery and validation in unique ovarian clear cell carcinoma models

  2019cites this paper
• RAS-mediated oncogenic signaling pathways in human malignancies.

  2019cites this paper
• Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma.

  2019cites this paper
• New targeted therapies for adrenocortical carcinomas.

  2018cites this paper
• The efficacy of HRAS and CDK4/6 inhibitors in anaplastic thyroid cancer cell lines

  2018cites this paper
• Calcitonin and Carcinoembryonic Antigen for the Diagnosis and Management of Medullary Thyroid Carcinoma

  2018cites this paper
• New insights and future perspectives in the therapeutic strategy of adrenocortical carcinoma (Review).

  2017cites this paper
• Medullary Thyroid Cancer: Clinical Characteristics and New Insights into Therapeutic Strategies Targeting Tyrosine Kinases

  2017cites this paper
• Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review

  2017cites this paper
• Targeted therapies in thyroid cancer: an extensive review of the literature

  2016cites this paper
• Recent Updates on the Management of Medullary Thyroid Carcinoma

  2016cites this paper
• Thyroglobulin fluctuations in patients with iodine-refractory differentiated thyroid carcinoma on lenvatinib treatment – initial experience

  2016cites this paper
• RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients

  2016cites this paper
• Future directions in the diagnosis and medical treatment of adrenocortical carcinoma.

  2016cites this paper
• Diagnosis, treatment, and prognosis in patients with liver metastases from follicular thyroid carcinoma (FTC).

  2015cites this paper
• Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment

  2015cites this paper
• Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells.

  2015cites this paper
• New Treatment Options for Metastatic Thyroid Cancer.

  2015cites this paper
• RAS proto-oncogene in medullary thyroid carcinoma.

  2015cites this paper
• Targeting drivers of melanoma with synthetic small molecules and phytochemicals.

  2015cites this paper
• Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE)

  2015cites this paper
• A straight forward synthesis of 4-aryl substituted 2-quinolones via Heck reaction

  2014cites this paper
• Adrenocortical carcinoma.

  2014cites this paper
• Emerging therapy for adrenocortical carcinoma.

  2014cites this paper
• New therapeutic options for advanced forms of thyroid cancer

  2014cites this paper
• Synthesis of Multifunctional 3‐Amino‐4‐phosphono‐2‐quinolinones via Regioselective Ring Enlargement of Imino Isatins

  2014cites this paper
• Towards combinatorial targeted therapy in melanoma: From pre-clinical evidence to clinical application (Review)

  2014cites this paper
• Targeted therapy with kinase inhibitors in aggressive endocrine tumors

  2013influential citation
• Arterial thrombotic events and acute coronary syndromes with cancer drugs: are growth factors the missed link?: what both cardiologist and oncologist should know about novel angiogenesis inhibitors.

  2013cites this paper
• Multiple Endocrine Neoplasia Type 2 and Bone

  2013cites this paper
• Copper-Catalyzed Aerobic Oxidative Carbocyclization– Ketonization Cascade: Selective Synthesis of Quinolinones

  2013cites this paper
• Molecularly Targeted Therapies in Metastatic Pancreatic Cancer: A Systematic Review

  2013cites this paper
• Treatment directed to signalling molecules in patients with advanced differentiated thyroid cancer.

  2013influential citation
• Targeted Therapies in Melanoma: Successes and Pitfalls

  2013cites this paper
• Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.

  2013cites this paper
• Scandium-catalyzed preparation of cytotoxic 3-functionalized quinolin-2-ones: Regioselective ring enlargement of isatins or imino isatins

  2012cites this paper
• Differentiated thyroid cancers: a comprehensive review of novel targeted therapies

  2012cites this paper
• Targeted agents for the treatment of metastatic melanoma

  2012cites this paper
• Current and future medical therapy, and the molecular features of adrenocortical cancer.

  2012cites this paper
• Current and Emerging Therapeutic Options in Adrenocortical Cancer Treatment

  2012cites this paper
• Targeting DNA damage and repair: embracing the pharmacological era for successful cancer therapy.

  2012cites this paper
• Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies (review).

  2012cites this paper
• Transient partial response to sorafenib treatment in an adolescent patient with MEN2B Syndrome and end‐stage medullary thyroid carcinoma

  2012cites this paper
• Randomized Phase II Trial of Sorafenib with Temsirolimus or Tipifarnib in Untreated Metastatic Melanoma (S0438)

  2012cites this paper
• Design, synthesis, and characterization of piperazinedione-based dual protein inhibitors for both farnesyltransferase and geranylgeranyltransferase-I.

  2011cites this paper
• [Use of new molecules in the treatment of advanced thyroid cancer].

  2011cites this paper
• Current and emerging therapies for advanced adrenocortical carcinoma.

  2011cites this paper
• Title : Role of BRAF in Thyroid Oncogenesis

  2011cites this paper
• Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.

  2011influential citation
• Molecular Pathways Role of BRAF in Thyroid Oncogenesis

  2011cites this paper
• Ras in cancer and developmental diseases.

  2011cites this paper
• Targeted therapies and thyroid cancer: an update

  2011cites this paper
• Role of BRAF in Thyroid Oncogenesis

  2011cites this paper
• Molecular targeted approaches for treatment of pancreatic cancer.

  2011cites this paper
• Update on the molecular signature of differentiated thyroid cancer: clinical implications and potential opportunities

  2011cites this paper
• Use of new molecules in the treatment of advanced thyroid cancer

  2011cites this paper
• Uso de nuevas moléculas en el tratamiento del cáncer avanzado de tiroides

  2011cites this paper
• Ruthenium-catalyzed intramolecular carbocyclization of alkynes with an sp3carbon involving an oxidative deprotonation process

  2011cites this paper
• Targeted therapies for advanced thyroid cancer

  2011cites this paper
• Medullary Thyroid Carcinoma: Molecular Signaling Pathways and Emerging Therapies

  2011cites this paper
• Controlled rearrangement of lactam-tethered allenols with brominating reagents: a combined experimental and theoretical study on α- versus β-keto lactam formation.

  2011cites this paper
• Oncogenetics of melanoma: basis for molecular diagnostics and therapy

  2011cites this paper
• Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growth

  2011cites this paper
• Farnesyltransferase inhibitors: where are we now?

  2010cites this paper
• Targeted treatment and new agents in diffuse large B cell lymphoma

  2010cites this paper
• Systemic Therapy of Non-Resectable Metastatic Melanoma

  2010cites this paper
• New approaches in the management of radioiodine-refractory thyroid cancer: the molecular targeted therapy era.

  2010cites this paper
• Molecular pathogenesis of follicular cell derived thyroid cancers.

  2010cites this paper
• Palladium-catalyzed intramolecular amidation of C(sp2)-H bonds: synthesis of 4-aryl-2-quinolinones.

  2010cites this paper
• Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements

  2010cites this paper
• Sorafenib: rays of hope in thyroid cancer.

  2010cites this paper
• Treatment with sorafenib in advanced thyroid cancer - a case report.

  2010cites this paper
• Targeted molecular therapies in thyroid carcinoma Terapias moleculares direcionadas em câncer de tireoide

  2009cites this paper
• Targeted molecular therapies in thyroid carcinoma.

  2009cites this paper
• : a consensus statement of the Italian Society of Endocrinology

  year unknowncites this paper
• ENDOCRINOLOGÍA Y NUTRICIÓN

  year unknowncites this paper